Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.71 and traded as high as $3.89. Sonoma Pharmaceuticals shares last traded at $3.62, with a volume of 67,888 shares traded.

Wall Street Analyst Weigh In

SNOA has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Monday, November 24th. Wall Street Zen upgraded Sonoma Pharmaceuticals to a “hold” rating in a report on Friday, October 3rd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Sonoma Pharmaceuticals has an average rating of “Sell”.

Sonoma Pharmaceuticals Stock Performance

The stock has a 50-day moving average of $3.71 and a two-hundred day moving average of $3.71. The company has a market cap of $6.15 million, a P/E ratio of -1.65 and a beta of 1.64.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Tuesday, November 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.18. Sonoma Pharmaceuticals had a negative return on equity of 45.46% and a negative net margin of 20.57%. Research analysts predict that Sonoma Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management bought a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.